The health systems will serve as recruiting centers and partners in the second phase of the validation stage of the study, named DeCODe. Digital health company PhysIQ is leading the study, which aims to identify the earliest signals of an inflammatory response specific to an individual who has COVID-19, according to the May 25 news release.
Developing the biomarker also may provide early detection of a rapid clinical decompensation in high-risk COVID-19 patients.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
